Associated Genetic Biomarkers
MLANA status serves as an inclusion eligibility criteria in 3 clinical trials, of which 0 are open and 3 are closed. Of the trials that contain MLANA status as an inclusion criterion, 1 is early phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open).
Trials with MLANA status in the inclusion eligibility criteria most commonly target melanoma .
The most frequent alterations to serve as inclusion eligibility criteria are MLANA Expression and MLANA Overexpression .
Aldesleukin and melanoma antigen-specific cd8+ t lymphocytes are the most frequent therapies in trials with MLANA as an inclusion criteria .
Significance of MLANA in Diseases
MLANA is an inclusion criterion in 3 clinical trials for melanoma, of which 0 are open and 3 are closed. Of the trials that contain MLANA status and melanoma as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.